Sweden

Iconovo

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

ISR Signs Agreement with Iconovo for Development of Inhaled Covid-19 Vaccine

Lead Product(s): Adjuvanted SARS-CoV-2 spike proteins

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Vaccine

Partner/Sponsor/Collaborator: Immune System Regulation

Deal Size: $1.0 million Upfront Cash: Undisclosed

Deal Type: Agreement April 01, 2021

Details:

ISR will have exclusive rights to use ICOone for treating Covid-19 and its variants with a technology based on spike proteins with an adjuvant. Iconovo will develop an inhalation product for the purpose of testing it in a human clinical trial.

Dilafor AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Dilafor Initiates Collaboration with Liverpool University to Study the Effect of Tafoxiparin on SARS-CoV-2

Lead Product(s): Tafoxiparin

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Large molecule

Partner/Sponsor/Collaborator: Liverpool University

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration April 17, 2020

Details:

Liverpool University with Keele University will study Tafoxiparin in order to find an effective treatment of patients who’ve been struck by COVID-19 virus.